In a significant development for pregnant women and healthcare providers, a large-scale study spearheaded by Harvard T.H. Chan School of Public Health has found no evidence to suggest that the antiseizure medication topiramate increases the risk of autism spectrum disorder (ASD) in children when taken during pregnancy. According to Harvard Gazette, the drug, widely used to treat conditions such as epilepsy, migraines, and bipolar disorder, has come under the scanner in a study involving nearly 4.3 million pregnant women and their offspring.
The research, recently published in the New England Journal of Medicine, tracked the incidence of ASD among the children of mothers with epilepsy and found a higher prevalence of ASD at age 8, what's not surprising given the generally recognized increased risk associated with neurological conditions. The extended study, which consolidated two decades worth of data from 2000 to 2020, also evaluated children exposed to other antiseizure medications such as valproate and lamotrigine, serving as control groups to solidify the findings related to topiramate. While past studies have raised concerns, "Our findings provide needed clarity on the possible neurodevelopmental impacts of this commonly used drug," lead author Sonia Hernández-Díaz, a professor of epidemiology, told Harvard Gazette.
Amid the numbers crunched and analyzed, researchers reported that among the children in the study, 1.9 percent of those who had never been exposed to an antiseizure medication were diagnosed with ASD. In contrast, among children born to mothers with epilepsy, the rates were 4.2 percent without antiseizure medication exposure, 6.2 percent with topiramate exposure, 10.5 percent with valproate, and 4.1 percent with lamotrigine. After factoring in various influencing factors, the study concluded that topiramate and lamotrigine were not associated with an increased risk of ASD, while valproate continued to show a connection to a higher risk. This crystallizes the complex, nuanced relationship between maternal health, medication, and child developmental outcomes.
While the study throws light on the supposed safety of topiramate from a neurodevelopmental perspective, the authors underscored that the medication is still associated with a higher risk of oral clefts in children, a separate concern that prescribers must weigh against potential benefits. The research also comes with its limitations, such as a significant number of children lost to follow-up by age 8 which could impact the study's findings, despite the substantial sample size and extensive data set, this makes it crucial for ongoing monitoring and research in the field to continue, a point also echoed by Krista Huybrechts, an associate professor in the Department of Epidemiology and co-author of the study. Funded by the National Institute of Mental Health, the research serves as an indispensable resource for guiding future healthcare policies and patient counseling.
